Sujal  Shah net worth and biography

Sujal Shah Biography and Net Worth

Mr. Shah has served as our President and Chief Executive Officer since March 2017. Previously, he served as our Chief Financial Officer since December of 2013. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Board of Tvardi Therapeutics. Mr. Shah received a M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.

What is Sujal Shah's net worth?

The estimated net worth of Sujal Shah is at least $5.56 million as of December 11th, 2023. Mr. Shah owns 171,301 shares of CymaBay Therapeutics stock worth more than $5,563,856 as of April 23rd. This net worth evaluation does not reflect any other assets that Mr. Shah may own. Additionally, Mr. Shah receives an annual salary of $1,040,000.00 as CEO at CymaBay Therapeutics. Learn More about Sujal Shah's net worth.

How old is Sujal Shah?

Mr. Shah is currently 51 years old. There are 7 older executives and no younger executives at CymaBay Therapeutics. Learn More on Sujal Shah's age.

What is Sujal Shah's salary?

As the CEO of CymaBay Therapeutics, Inc., Mr. Shah earns $1,040,000.00 per year. Learn More on Sujal Shah's salary.

How do I contact Sujal Shah?

The corporate mailing address for Mr. Shah and other CymaBay Therapeutics executives is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. CymaBay Therapeutics can also be reached via phone at (510) 293-8800 and via email at [email protected]. Learn More on Sujal Shah's contact information.

Has Sujal Shah been buying or selling shares of CymaBay Therapeutics?

Sujal Shah has not been actively trading shares of CymaBay Therapeutics during the last quarter. Most recently, Sujal Shah sold 64,865 shares of the business's stock in a transaction on Monday, December 11th. The shares were sold at an average price of $20.00, for a transaction totalling $1,297,300.00. Following the completion of the sale, the chief executive officer now directly owns 171,301 shares of the company's stock, valued at $3,426,020. Learn More on Sujal Shah's trading history.

Who are CymaBay Therapeutics' active insiders?

CymaBay Therapeutics' insider roster includes Janet Dorling (Director), Dennis Kim (Insider), Charles McWherter (Insider), Daniel Menold (VP), Paul Quinlan (General Counsel), Sujal Shah (CEO), and Kurt von Emster (Director). Learn More on CymaBay Therapeutics' active insiders.

Are insiders buying or selling shares of CymaBay Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 480,648 shares worth more than $7,806,823.97. The most recent insider tranaction occured on February, 12th when Director Janet Dorling sold 6,000 shares worth more than $191,820.00. Insiders at CymaBay Therapeutics own 7.0% of the company. Learn More about insider trades at CymaBay Therapeutics.

Information on this page was last updated on 2/12/2024.

Sujal Shah Insider Trading History at CymaBay Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/11/2023Sell64,865$20.00$1,297,300.00171,301View SEC Filing Icon  
10/9/2023Sell64,861$14.20$921,026.20171,301View SEC Filing Icon  
6/6/2022Buy51,301$1.95$100,036.95171,301View SEC Filing Icon  
10/10/2019Buy5,000$4.30$21,500.00120,000View SEC Filing Icon  
9/23/2019Buy5,000$5.53$27,650.00111,900View SEC Filing Icon  
9/20/2019Buy1,900$5.50$10,450.00111,900View SEC Filing Icon  
12/21/2018Buy10,000$6.54$65,400.00110,000View SEC Filing Icon  
10/15/2018Buy5,000$9.90$49,500.00100,000View SEC Filing Icon  
7/27/2018Buy5,000$10.90$54,500.0095,000View SEC Filing Icon  
5/11/2018Buy5,000$10.65$53,250.0090,000View SEC Filing Icon  
7/20/2017Buy10,000$7.34$73,400.0075,891View SEC Filing Icon  
4/5/2016Buy55,000$1.39$76,450.0042,000View SEC Filing Icon  
4/4/2016Buy22,000$1.39$30,580.0042,000View SEC Filing Icon  
5/18/2015Buy10,000$3.40$34,000.00View SEC Filing Icon  
See Full Table

Sujal Shah Buying and Selling Activity at CymaBay Therapeutics

This chart shows Sujal Shah's buying and selling at CymaBay Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CymaBay Therapeutics Company Overview

CymaBay Therapeutics logo
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.
Read More

Today's Range

Now: $32.48
Low: $32.48
High: $32.48

50 Day Range

MA: $32.38
Low: $32.12
High: $32.48

2 Week Range

Now: $32.48
Low: $7.26
High: $32.50

Volume

73 shs

Average Volume

4,113,430 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32